Filter Results:
(81)
Show Results For
- All HBS Web
(81)
- News (6)
- Research (52)
- Events (2)
- Multimedia (1)
- Faculty Publications (33)
Show Results For
- All HBS Web
(81)
- News (6)
- Research (52)
- Events (2)
- Multimedia (1)
- Faculty Publications (33)
Page 1 of 81
Results →
- May 2015
- Case
Transforming Alkermes into a Global Biopharmaceutical Company
By: C. Fritz Foley and Nicholas Haas
In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about how to finance the acquisition of Dublin, Ireland-based Elan Drug Technologies (EDT)—a deal that was expected to close in the fall. The case describes the history of Alkermes, provides information... View Details
Keywords: Financing; Debt; Merger; CFO; Financial Management; Biotechnology Industry; Pharmaceutical Industry; United States; Europe
Foley, C. Fritz, and Nicholas Haas. "Transforming Alkermes into a Global Biopharmaceutical Company." Harvard Business School Case 215-079, May 2015.
- January 2022 (Revised July 2022)
- Case
Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A
By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
Chandra, Amitabh, Paul Clancy, and Craig Garthwaite. "Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A." Harvard Business School Case 622-075, January 2022. (Revised July 2022.)
- July 2022
- Teaching Note
Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A
By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
Teaching Note for HBS Case No. 622-075. View Details
- July 2022
- Supplement
Gilead Sciences: Developing a Biopharmaceutical Pipeline Through M&A (Spreadsheet Supplement)
By: Amitabh Chandra, Paul Clancy and Craig Garthwaite
- Spring 2014
- Article
Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company
By: Andrew Knauer and George Serafeim
Faced with a large percentage of investors that chase short-term returns, companies could benefit by attracting investors with longer-term horizons and incentives that are more consistent with the long-term strategy of the company. The managers of most companies take... View Details
Keywords: Investing; Asset Management; Long-term Investing; Short-termism; Sustainability; Integrated Reporting; Leadership & Corporate Accountability; Pharmaceuticals; Leadership; Integrated Corporate Reporting; Investment; Business and Stakeholder Relations; Corporate Finance; Biotechnology Industry; Pharmaceutical Industry
Knauer, Andrew, and George Serafeim. "Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company." Journal of Applied Corporate Finance 26, no. 2 (Spring 2014): 57–64.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Pharmaceutical Industry; Biotechnology Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 01 Mar 2007
- News
Pharma Suits a Farm Gal
GRAHAM: From rodeo to CEO. Amylin Pharmaceuticals CEO Ginger Graham (MBA ’86) had a good year in 2006, with Amylin stock up as much as 45 percent, with Byetta and Symlin, its two innovative diabetes drugs, performing well, and with the company added to the Nasdaq 100.... View Details
- April 2023
- Case
Elliott Management: Capital Allocation in Biopharma
By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an... View Details
Keywords: Finance; Strategy; Capital Allocation; Biopharmaceutical Industry; Shareholder Activism; Investment Activism; Resource Allocation; Research and Development; Business and Shareholder Relations; Corporate Strategy; Pharmaceutical Industry
Chandra, Amitabh, Paul Clancy, and Lauren Gunasti. "Elliott Management: Capital Allocation in Biopharma." Harvard Business School Case 623-045, April 2023.
- 01 Dec 2013
- News
Your Own Medicine
WILLIAMS CHARLEY SECKLER in the midst of the first-ever trial for a DMD treatment at Johns Hopkins University. Photo courtesy the Seckler Family by Dan Morrell There's this picture of Charley Seckler from last summer that his mom has sent to everyone: Her 12-year-old... View Details
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details
Keywords: R＆D Investments; Drug Development; Product Shocks; M＆A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry
Krieger, Joshua L., Xuelin Li, and Richard T. Thakor. "Find and Replace: R&D Investment Following the Erosion of Existing Products." Management Science 68, no. 9 (September 2022): 6552–6571.
- 12 Nov 2019
- Video
Kiran Mazumdar-Shaw
Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, relates how gender bias set her on a path to invest in industrial enzymes and the foundation of... View Details
- 12 Nov 2019
- Video
Kiran Mazumdar Shaw
Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, explains how her firm developed over four years a new technology for making insulin, an essential... View Details
- 12 Nov 2019
- Video
Kiran Mazumdar-Shaw
Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, discusses how the firm has been able to create a world class innovation center in Bangalore despite... View Details
- May 1998 (Revised May 1999)
- Case
Biopure Corp.
It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood... View Details
Keywords: Segmentation; Marketing Strategy; Engineering; Budgets and Budgeting; Sales; Transformation; Markets; Debates; Product Launch; Pharmaceutical Industry
Gourville, John T. "Biopure Corp." Harvard Business School Case 598-150, May 1998. (Revised May 1999.)
- 12 Nov 2019
- Video
Kiran Mazumdar-Shaw
Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, discusses her ambition to promote women’s careers, noting that although 30 per cent of company... View Details
- 12 Nov 2019
- Video
Kiran Mazumdar Shaw
Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India’s largest biopharmaceutical company, discusses how partnerships with Unilever, Cuban research institutes, and the global health companies... View Details
- November 2017
- Case
BeiGene
By: Willy Shih and Jimmy Zhang
BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details
Keywords: Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Business Startups; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; China
Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.
- January 2005 (Revised March 2006)
- Case
Molecular Insight Pharmaceuticals, Inc.
By: Richard G. Hamermesh and Edwin W. Parkinson III
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing.... View Details
Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Health Industry
Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)
- February 2010 (Revised April 2010)
- Case
Organization and Strategy at Millennium (A)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Biotechnology Industry; Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)